too much......
Yes, the patent for Plavix (clopidogrel) expired on May 17, 2012. This expiration allowed for the introduction of generic versions of the medication, leading to increased accessibility and lower prices for patients. The patent expiration was significant as Plavix was one of the top-selling drugs worldwide before generics became available.
The patent-adjusted expiration for this product occurs when the patent protection expires.
The patent expires in 2017. You don't have all that long to wait.
Once a patent expires, the invention can be manufactured by anyone.
No, once a patent expires the invention is public domain and can never be patented again.
Yes.
Plavix Generic? Yes, the brand name medication Plavix will eventually come off patent. As a matter of fact about two years ago there was a generic on the market in the US but it got pulled off the market - I believe the name brand manufacturer (Bristol-Myers Squibb) won a patent extension. However, other countries do offer generics before they come available in the US. For example, Plavix equivalents are available now, manufactured by CIPLA Pharmaceuticals in India.
Generic for Plavix (Clopidogrel) is used to prevent blood clots in people with recent heart attack or stroke. Cheap Generic Plavix, 50 Tablets of Plavix 75mg, would cost about $60.42.
Patents apply to any machine created under that patent until the patent expires. It does not matter how many times the machine is used or how many times it changes hands, the patent is still a patent.
Vyvanse will become available to be made generically in June 2023 when the first patent expires.
Under US patent laws and procedures, the USPTO can suspend an application for a patent for various reasons. However, after a patent is issued, a patent generally expires naturally, although (in theory) a federal court can order that certain unlawfully obtained portions (claims) can be cancelled, or that the termination date of a particular patent be changed to correspond to that of an earlier-filed application (effectively shortening the duration of the second patent).
Nearly all Garst brand or Syngenta group beans are r/r, and of course, the same applies to Monsanto's seeds, as the owner of the Roundup patent and the roundup-ready patent. The r/r patent expires in 2014, after which farmers will still be able to find r/r seeds, or seeds that tolerate its generic glyphosate equivalent. Monsanto also claims that they will not sue farmers who keep r/r seeds from their own crop to replant after the patent expires.